OncoImmunity will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.
OncoImmunity, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies in a clinically actionable time frame.
AI-driven drug discovery business
NEC announced its business strategy surrounding its AI-driven drug discovery business in May 2019. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines, it states. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.
“The OncoImmunity AS team are delighted to be joining the NEC Group and firmly believe that the union will realize great synergies, marrying the mutual strengths of OncoImmunity AS’s and NEC’s neoantigen prediction pipelines with NEC’s expertise in AI, data management and security. These synergies will help strengthen NEC’s individualized immunotherapy programs, whilst simultaneously positioning NEC OncoImmunity AS as the leading neoantigen prediction service provider in the field,” said Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity AS.
Photo of Richard Stratford: Oslo Cancer Cluster Innovation Park